ABBV vs. IBM: A Head-to-Head Stock Comparison
Updated onHere’s a clear look at ABBV and IBM, comparing key factors like historical performance, profitability, financial strength, growth, dividend, and valuation.
Company Profile
| Symbol | ABBV | IBM |
|---|---|---|
| Company Name | AbbVie Inc. | International Business Machines Corporation |
| Country | United States | United States |
| GICS Sector | Health Care | Information Technology |
| GICS Industry | Biotechnology | IT Services |
| Market Capitalization | 413.22 billion USD | 268.62 billion USD |
| Exchange | NYSE | NYSE |
| Listing Date | January 2, 2013 | January 2, 1962 |
| Security Type | Common Stock | Common Stock |
Historical Performance
This chart compares the performance of ABBV and IBM by tracking the growth of an initial $10,000 investment in each. Use the tabs to select the desired time period. Data is adjusted for dividends and splits.
Historical Performance at a Glance
| Symbol | ABBV | IBM |
|---|---|---|
| 5-Day Price Return | 4.82% | 3.06% |
| 13-Week Price Return | 23.58% | -1.23% |
| 26-Week Price Return | 11.64% | 15.97% |
| 52-Week Price Return | 18.84% | 31.24% |
| Month-to-Date Return | 1.02% | 2.20% |
| Year-to-Date Return | 31.63% | 31.18% |
| 10-Day Avg. Volume | 6.76M | 5.87M |
| 3-Month Avg. Volume | 5.66M | 4.73M |
| 3-Month Volatility | 23.82% | 26.49% |
| Beta | 0.36 | 0.67 |
Profitability
Return on Equity (TTM)
ABBV
95.59%
Biotechnology Industry
- Max
- 97.92%
- Q3
- 11.99%
- Median
- -19.30%
- Q1
- -51.29%
- Min
- -132.03%
In the upper quartile for the Biotechnology industry, ABBV’s Return on Equity of 95.59% signals a highly effective use of shareholder capital to drive profitability compared to most of its peers.
IBM
21.99%
IT Services Industry
- Max
- 32.78%
- Q3
- 19.28%
- Median
- 13.86%
- Q1
- 5.50%
- Min
- -10.00%
In the upper quartile for the IT Services industry, IBM’s Return on Equity of 21.99% signals a highly effective use of shareholder capital to drive profitability compared to most of its peers.
Net Profit Margin (TTM)
ABBV
6.45%
Biotechnology Industry
- Max
- 73.34%
- Q3
- 18.98%
- Median
- -12.96%
- Q1
- -105.72%
- Min
- -259.82%
ABBV’s Net Profit Margin of 6.45% is aligned with the median group of its peers in the Biotechnology industry. This indicates its ability to convert revenue into profit is typical for the sector.
IBM
9.11%
IT Services Industry
- Max
- 19.71%
- Q3
- 11.01%
- Median
- 6.66%
- Q1
- 2.96%
- Min
- -6.22%
IBM’s Net Profit Margin of 9.11% is aligned with the median group of its peers in the IT Services industry. This indicates its ability to convert revenue into profit is typical for the sector.
Operating Profit Margin (TTM)
ABBV
18.80%
Biotechnology Industry
- Max
- 78.85%
- Q3
- 21.90%
- Median
- -13.30%
- Q1
- -109.94%
- Min
- -278.10%
ABBV’s Operating Profit Margin of 18.80% is around the midpoint for the Biotechnology industry, indicating that its efficiency in managing core business operations is typical for the sector.
IBM
9.77%
IT Services Industry
- Max
- 22.44%
- Q3
- 14.90%
- Median
- 8.82%
- Q1
- 4.91%
- Min
- -9.89%
IBM’s Operating Profit Margin of 9.77% is around the midpoint for the IT Services industry, indicating that its efficiency in managing core business operations is typical for the sector.
Profitability at a Glance
| Symbol | ABBV | IBM |
|---|---|---|
| Return on Equity (TTM) | 95.59% | 21.99% |
| Return on Assets (TTM) | 2.73% | 4.12% |
| Net Profit Margin (TTM) | 6.45% | 9.11% |
| Operating Profit Margin (TTM) | 18.80% | 9.77% |
| Gross Profit Margin (TTM) | 70.93% | 57.57% |
Financial Strength
Current Ratio (MRQ)
ABBV
0.74
Biotechnology Industry
- Max
- 16.97
- Q3
- 8.39
- Median
- 4.11
- Q1
- 2.64
- Min
- 0.74
ABBV’s Current Ratio of 0.74 falls into the lower quartile for the Biotechnology industry. This indicates a tighter liquidity situation and a more constrained capacity to handle short-term debt than many of its competitors.
IBM
0.91
IT Services Industry
- Max
- 3.17
- Q3
- 2.00
- Median
- 1.47
- Q1
- 1.05
- Min
- 0.52
IBM’s Current Ratio of 0.91 falls into the lower quartile for the IT Services industry. This indicates a tighter liquidity situation and a more constrained capacity to handle short-term debt than many of its competitors.
Debt-to-Equity Ratio (MRQ)
ABBV
49.22
Biotechnology Industry
- Max
- 1.92
- Q3
- 0.79
- Median
- 0.12
- Q1
- 0.00
- Min
- 0.00
With a Debt-to-Equity Ratio of 49.22, ABBV operates with exceptionally high leverage compared to the Biotechnology industry norm. This suggests an aggressive reliance on debt financing, which can magnify returns but also significantly elevates financial risk.
IBM
2.33
IT Services Industry
- Max
- 3.11
- Q3
- 1.55
- Median
- 0.55
- Q1
- 0.17
- Min
- 0.00
IBM’s leverage is in the upper quartile of the IT Services industry, with a Debt-to-Equity Ratio of 2.33. While this approach can boost equity growth, it also exposes the company to greater financial vulnerability.
Interest Coverage Ratio (TTM)
ABBV
2.70
Biotechnology Industry
- Max
- 72.37
- Q3
- 1.03
- Median
- -9.59
- Q1
- -65.05
- Min
- -163.11
ABBV’s Interest Coverage Ratio of 2.70 is in the upper quartile for the Biotechnology industry, signifying a strong and healthy capacity to meet its interest payments from operating profits.
IBM
45.57
IT Services Industry
- Max
- 129.00
- Q3
- 56.00
- Median
- 11.69
- Q1
- 0.77
- Min
- -28.15
IBM’s Interest Coverage Ratio of 45.57 is positioned comfortably within the norm for the IT Services industry, indicating a standard and healthy capacity to cover its interest payments.
Financial Strength at a Glance
| Symbol | ABBV | IBM |
|---|---|---|
| Current Ratio (MRQ) | 0.74 | 0.91 |
| Quick Ratio (MRQ) | 0.48 | 0.80 |
| Debt-to-Equity Ratio (MRQ) | 49.22 | 2.33 |
| Interest Coverage Ratio (TTM) | 2.70 | 45.57 |
Growth
Revenue Growth
EPS Growth
Dividend
Dividend Yield (TTM)
ABBV
2.71%
Biotechnology Industry
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
ABBV’s Dividend Yield of 2.71% is exceptionally high, placing it well above the typical range for the Biotechnology industry. While this may seem attractive, an unusually high yield can sometimes be a warning sign, reflecting a falling stock price or market concerns about the dividend’s sustainability.
IBM
2.29%
IT Services Industry
- Max
- 2.79%
- Q3
- 1.76%
- Median
- 0.58%
- Q1
- 0.00%
- Min
- 0.00%
With a Dividend Yield of 2.29%, IBM offers a more attractive income stream than most of its peers in the IT Services industry, signaling a strong commitment to shareholder returns.
Dividend Payout Ratio (TTM)
ABBV
226.84%
Biotechnology Industry
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
At 226.84%, ABBV’s Dividend Payout Ratio is exceptionally high, exceeding the typical range for the Biotechnology industry. While this provides a significant return to shareholders, it may limit funds for reinvestment and could be difficult to sustain.
IBM
75.57%
IT Services Industry
- Max
- 107.85%
- Q3
- 52.62%
- Median
- 22.53%
- Q1
- 0.00%
- Min
- 0.00%
IBM’s Dividend Payout Ratio of 75.57% is in the upper quartile for the IT Services industry. This indicates a strong commitment to shareholder returns but also suggests that a smaller portion of earnings is retained for reinvestment compared to many peers.
Dividend at a Glance
| Symbol | ABBV | IBM |
|---|---|---|
| Dividend Yield (TTM) | 2.71% | 2.29% |
| Dividend Payout Ratio (TTM) | 226.84% | 75.57% |
Valuation
Price-to-Earnings Ratio (TTM)
ABBV
111.05
Biotechnology Industry
- Max
- 40.44
- Q3
- 39.37
- Median
- 22.12
- Q1
- 15.76
- Min
- 3.48
At 111.05, ABBV’s P/E Ratio is exceptionally high, exceeding the typical maximum for the Biotechnology industry. This suggests the stock may be significantly overvalued compared to its peers and implies high market expectations that could be difficult to meet.
IBM
46.41
IT Services Industry
- Max
- 56.41
- Q3
- 33.17
- Median
- 23.17
- Q1
- 16.18
- Min
- 6.62
A P/E Ratio of 46.41 places IBM in the upper quartile for the IT Services industry. This high valuation relative to peers suggests the market holds elevated expectations for the company’s future growth.
Price-to-Sales Ratio (TTM)
ABBV
7.16
Biotechnology Industry
- Max
- 92.67
- Q3
- 41.36
- Median
- 8.45
- Q1
- 4.46
- Min
- 0.97
ABBV’s P/S Ratio of 7.16 aligns with the market consensus for the Biotechnology industry. This suggests its valuation, based on sales, is seen as standard and is on par with its competitors.
IBM
4.23
IT Services Industry
- Max
- 5.99
- Q3
- 4.26
- Median
- 1.93
- Q1
- 0.97
- Min
- 0.12
IBM’s P/S Ratio of 4.23 aligns with the market consensus for the IT Services industry. This suggests its valuation, based on sales, is seen as standard and is on par with its competitors.
Price-to-Book Ratio (MRQ)
ABBV
261.01
Biotechnology Industry
- Max
- 22.72
- Q3
- 10.68
- Median
- 4.55
- Q1
- 2.44
- Min
- 0.59
At 261.01, ABBV’s P/B Ratio is at an extreme premium to the Biotechnology industry. This signifies that the market’s valuation is heavily reliant on future potential rather than its current net asset value, which can be a high-risk proposition.
IBM
9.96
IT Services Industry
- Max
- 12.34
- Q3
- 7.54
- Median
- 3.84
- Q1
- 2.52
- Min
- 0.88
IBM’s P/B Ratio of 9.96 is in the upper tier for the IT Services industry. This indicates that investors are paying a premium relative to the company’s net assets, a valuation that hinges on its ability to generate superior profits.
Valuation at a Glance
| Symbol | ABBV | IBM |
|---|---|---|
| Price-to-Earnings Ratio (TTM) | 111.05 | 46.41 |
| Price-to-Sales Ratio (TTM) | 7.16 | 4.23 |
| Price-to-Book Ratio (MRQ) | 261.01 | 9.96 |
| Price-to-Free Cash Flow Ratio (TTM) | 22.91 | 23.03 |